Keros doses first patient in Phase 2 trial of rinvatercept for Duchenne muscular dystrophy
Keros Therapeutics said initial data from the open-label study are expected in the first half of 2027.
SEC filing
Latest
4 stories
Monday, September 28
Monday, August 3
Keros reports second-quarter 2026 results as Phase 2 rinvatercept DMD trial gets underway
Keros initiated its Phase 2 trial of rinvatercept in Duchenne muscular dystrophy and still expects initial data in the first half of 2027, while cash fell to $257.6 million.
SEC filing
Wednesday, July 22
Keros Therapeutics CFO Keith Regnante resigns, interim replacement named
Keros said Regnante will leave August 3, 2026, with Corporate Controller Annita Tanini stepping in as interim finance chief the next day.
SEC filing